Key Stats for Jazz Pharmaceuticals Stock
- Past-Week Performance: +1.2%
- 52-Week Range: $95.5 to $198
- Current Price: $180.6
What Happened?
Jazz Pharmaceuticals (JAZZ), an Ireland-based specialty biopharma focused on rare disease, sleep, and oncology, delivered a $4.3B revenue record in 2025 while simultaneously completing a pipeline transformation that makes the next two years its most catalyst-dense period in history, with the stock trading at $180.62 against a median analyst target of $219.50.
JAZZ’ Q4 2025 results cleared every consensus bar, with revenue of $1.20B beating the $1.17B IBES estimate and non-GAAP adjusted EPS of $6.64 topping the $6.52 consensus, while the company guided 2026 total revenue to $4.25B–$4.50B and confirmed the sBLA submission for zanidatamab, its HER2-targeted antibody, was complete and the PDUFA review clock had started.
Xywav, the low-sodium version of the sleep drug oxybate prescribed for narcolepsy and idiopathic hypersomnia, grew 12% to $1.7B in 2025 and added over 2,000 net patients for the year, while Modeyso, a brain cancer therapy launched in August for a tumor type with no prior approved drug, generated $48M in just 4.5 months and has a peak U.S. sales target above $500M.
CFO Phil Johnson stated at the TD Cowen 46th Annual Health Care Conference last March 3 that “we’ve now completed the filing for the sBLA for GEA,” then confirmed the FDA had assigned zanidatamab breakthrough designation, accelerating the path toward a potential second-half 2026 launch in first-line gastroesophageal adenocarcinoma.
Zanidatamab’s Horizon GEA trial delivered 26.4 months median overall survival in the triplet arm versus roughly 20 months on the current Keytruda-based standard, the ACTION first-line Modeyso trial carries a late-2026 or early-2027 OS readout, and the EmpowHER breast cancer trial targeting 150,000 HER2-positive patients completes enrollment in the first half of 2027, together forming a multi-indication growth engine that sits alongside a $2.2B epilepsy and oncology base already guided to double-digit growth in 2026.
Wall Street’s Take on JAZZ Stock
The Q4 beat and full-year guidance confirmation matter less than what the forward EBITDA model reveals: the 2025 margin collapse to 17.2% was driven by one-time litigation settlements and acquisition costs, not structural deterioration, and 2026 consensus sees EBITDA snapping back to $2.03B at a 45.6% margin.
Normalized EPS tells the same story more sharply, with consensus projecting $23.92 in 2026 against the $8.38 reported in 2025, a 185.5% surge supported by Modeyso’s $48M launch ramp, Epidiolex’s blockbuster $1.1B base growing double digits, and the pending zanidatamab GEA launch that carries its own revenue stream in the second half of 2026.
Moreover, JAZZ’ free cash flow slipped modestly from $1.36B in 2024 to $1.30B in 2025 despite absorbing one-time litigation settlements and acquisition costs tied to the Chimerix deal, and consensus projects $1.56B in 2026 at a 35% FCF margin, a 19.9% jump driven by Modeyso’s commercial ramp, the anticipated zanidatamab GEA launch revenue in the second half of 2026, and Epidiolex’s double-digit growth on a $1.1B base.
Fourteen analysts currently cover JAZZ with 9 buys, 5 outperforms, 2 holds, and zero sells; the mean price target sits at $223.50 and the median at $225.50, representing 23.7% upside from the March 20 close of $180.62, with the Street specifically anchoring conviction to the zanidatamab GEA approval and Modeyso’s commercial trajectory.
The analyst target range spans $188.00 on the low end to $275.00 on the high end, where the floor reflects Xywav erosion from generic high-sodium oxybate competition and orexin entry in the second half of 2026, and the ceiling assumes zanidatamab achieves priority review, launches in GEA on schedule, and the ACTION first-line Modeyso trial reads out positively.
What Does the Valuation Model Say?
The TIKR mid-case model prices JAZZ at $229.16 by December 31, 2030, implying a 26.9% total return at a 5.1% IRR, built on a mid-case revenue CAGR of 6.9% and a net income margin expanding to 37.0%, assumptions grounded in zanidatamab’s multi-indication pipeline, the Epidiolex exclusivity runway to the very late 2030s, and Modeyso’s $500M-plus peak U.S. sales target contingent on a positive ACTION readout.
The market is pricing JAZZ at roughly 8x NTM earnings despite a 185.5% normalized EPS inflection underway, treating the 2025 GAAP loss as representative when it was distortion.
Modeyso’s $37M Q4 alone, from a drug that launched in August with no prior approved competitor, directly validates the $500M-plus peak sales assumption embedded in the TIKR model’s 6.9% revenue CAGR.
CFO Phil Johnson confirmed at TD Cowen on March 3 that the sBLA submission for zanidatamab was complete and breakthrough designation secured, signaling FDA is treating this data as practice-changing, not routine.
The TIKR model breaks if Xywav erodes faster than guided in the second half of 2026, as rare sleep revenue at $1.8B–$1.9B currently anchors nearly half of total sales and any payer-driven step-edit favoring generics would compress the FCF base before the oncology ramp offsets it.
The single number to watch is the zanidatamab PDUFA date, which will arrive imminently following the March 3 sBLA completion, confirming whether a second-half 2026 GEA launch, the key near-term revenue catalyst absent from 2025 actuals, is on track.
Should You Invest in Jazz Pharmaceuticals plc?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up JAZZ stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Jazz Pharmaceuticals plc alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JAZZ stock on TIKR for Free →
